Background-S100A9 is constitutively expressed in neutrophils, dendritic cells, and monocytes; is associated with acute and chronic inflammatory conditions; and is implicated in obesity and cardiovascular disease in humans. Most of the constitutively secreted S100A9 is derived from myeloid cells. A recent report demonstrated that mice deficient in S100A9 exhibit reduced atherosclerosis compared with controls and suggested that this effect was due in large part to loss of S100A9 in bone marrow-derived cells. Methods and Results-To directly investigate the role of bone marrow-derived S100A9 in atherosclerosis and insulin resistance in mice, low-density lipoprotein receptor-deficient, S100A9-deficient bone marrow chimeras were generated. Neither atherosclerosis nor insulin resistance was reduced in S100A9-deficient chimeras fed a diet rich in fat and carbohydrates. To investigate the reason for this lack of effect, myeloid cells were isolated from the peritoneal cavity or bone marrow. S100A9-deficient neutrophils exhibited a reduced secretion of cytokines in response to toll-like receptor-4 stimulation. In striking contrast, S100A9-deficient dendritic cells showed an exacerbated release of cytokines after toll-like receptor stimulation. Macrophages rapidly lost S100A9 expression during maturation; hence, S100A9 deficiency did not affect the inflammatory status of macrophages. Conclusions-S100A9 differentially modifies phenotypic states of neutrophils, macrophages, and dendritic cells. The effect of S100A9 deficiency on atherosclerosis and other inflammatory diseases is therefore predicted to depend on the relative contribution of these cell types at different stages of disease progression. Furthermore, S100A9 expression in nonmyeloid cells is likely to contribute to atherosclerosis. (Circulation. 2011;123:1216-1226.)
S 100A9 and its binding partner, S100A8, are members of the S100 family of proteins and are promising novel markers of cardiovascular risk in humans. 1 Recent studies on mice demonstrate that S100A8/A9 promote atherosclerosis. 2 Thus, S100A9 appears to be both a marker and a mediator of atherosclerosis. Furthermore, circulating levels of S100A8/A9 are increased in a number of autoimmune and proinflammatory states, including type 1 diabetes mellitus 3, 4 and obesity, 5 characterized by increased cardiovascular risk. Studies on S100A9-deficient mice suggest that S100A8/A9 have proinflammatory actions, eg, in sepsis 6, 7 and pancreatitis. 8 Clinical Perspective on p 1226 S100A8/A9 are abundantly and constitutively expressed in neutrophils and monocytes. Expression of S100A8/A9 is lost during differentiation of monocytes into macrophages, 9 yet some expression is sustained in dendritic cells (DCs). 10 S100A8/A9 promote migration of neutrophils through increased CD11b expression. 11 The effects of S100A9 deficiency in neutrophils might be due to the combined loss of S100A8 and S100A9 because S100A9-deficient neutrophils express S100A8 mRNA but not S100A8 protein, suggesting that S100A9 stabilizes S100A8. 11, 12 S100A8/A9 are secreted from phagocytes through a tubulin-dependent mechanism, 13 and extracellular functions include signaling through toll-like receptor (TLR)-4 and the receptor for advanced glycation end products, 6, 14 resulting in proinflammatory effects. 15 However, S100A8/A9 expression is also induced by antiinflammatory signals, 16, 17 and overexpression of S100A9 blocks maturation of DCs. 18 Thus, S100A8/A9 might exert inhibitory or antiinflammatory actions.
Because of the abundance of S100A8/A9 in myeloid cells compared with nonmyeloid cells, myeloid-derived S100A8/A9 are believed to mediate the effects of whole-body S100A9 deficiency. However, S100A8 and S100A9 can be induced by inflammatory stimuli in nonhematopoietic cells, eg, endothelial cells. 12, 19, 20 Therefore, the goal of this study was to investigate whether myeloid-derived S100A8/A9 contribute to atherosclerosis. Insulin resistance was analyzed as a secondary end point.
Our results demonstrate that bone marrow-derived S100A9 is not sufficient to promote atherosclerosis or insulin resistance in low-density lipoprotein receptor-deficient (LDLR Ϫ/Ϫ ) mice. Furthermore, we have uncovered disparate effects of S100A9 on the inflammatory phenotype of neutrophils, macrophages, and DCs. These findings suggest that the biological effects of S100A9 depend on the relative abundance of different immune cells and nonmyeloid cells in different disease states.
Methods

S100A9-Deficient Mice
SV129;C57BL/6J S100A9 Ϫ/Ϫ mice 11 were backcrossed 10 generations onto the C57BL/6J background, and a colony of S100A9 ϩ/Ϫ mice was used to generate S100A9 wild-type (S100A9 ϩ/ϩ ) and S100A9 Ϫ/Ϫ offspring. S100A9 Ϫ/Ϫ mice were viable with normal myelopoietic properties, consistent with previous studies. 9, 10 Male and female mice (10 to 15 weeks of age) were used for cell isolation. In vivo experiments included studies on male whole-body S100A9 Ϫ/Ϫ mice and bone marrow transplantations from S100A9 Ϫ/Ϫ and littermate S100A9 ϩ/ϩ donors into male LDLR Ϫ/Ϫ recipients. All animal studies were approved by the Institutional Animal Care and Use Committee at the University of Washington.
Cell Isolation
Peritoneal neutrophils and macrophages were collected 4 hours and 5 days after thioglycollate injection, respectively. Bone marrow-derived macrophages were differentiated in 30% L-conditioned medium (a source of macrophage colonystimulating factor), and DCs were differentiated in 3 to 10 ng/mL recombinant granulocyte macrophage colony-stimulating factor for 5 to 7 days. In some experiments, monocyte enrichment from bone marrow was achieved by use of a negative-selection monocyte-enrichment kit (Easy Sep, Vancouver, BC, Canada). Classic activation of DCs and macrophages was induced by a 24-hour exposure to 5 ng/mL lipopolysaccharide (LPS) plus 12 ng/mL interferon-␥ (IFN␥). To examine TLR activation, CD11 ϩ DCs were exposed to various concentrations of zymosan, LPS, CpG-B, and Pam3CSK4 overnight. T cells from spleen and peripheral lymph nodes were collected with subsequent immunomagnetic depletion of contaminating cells, as described in the online-only Data Supplement. More than 95% of these cells were CD4 ϩ or CD8 ϩ , as evaluated by flow cytometry.
Atherosclerosis and Insulin Resistance Studies
Male C57BL/6 whole-body S100A9 ϩ/ϩ and S100A9 Ϫ/Ϫ mice (10 to 12 weeks old) were fed a chow diet or a diabetogenic diet rich in fat and carbohydrates with 0.15% wt/wt cholesterol (DDC; BioServ No. F4997) for 12 weeks. Insulin resistance was evaluated by glucose and insulin tolerance tests at 10 and 12 weeks, respectively. The mice were then saline perfused, and epididymal fat was dissected, weighed, and fixed in paraformaldehyde.
After lethal irradiation, male LDLR Ϫ/Ϫ mice (12 to 14 weeks old) received intravenous bone marrow transplants from S100A9 ϩ/ϩ or S100A9 Ϫ/Ϫ mice. After a 3-week recovery period, the mice were fed chow or DDC for 24 weeks. Body weights were measured weekly, and blood glucose and blood cholesterol were determined at the beginning and end of the study. There were no differences in these measurements between the groups at baseline. Glucose and insulin tolerance tests were performed at 20 and 22 weeks, respectively. At the end of the 24-week study, mice were saline perfused under physiological pressure. Epididymal fat pads, heart, and the brachiocephalic artery were dissected, fixed, embedded, and serial sectioned. Every fourth section was stained with a Movat pentachrome stain. 21 Adjacent sections were stained with antibodies against S100A9, Ly6G, Mac-2, and major histocompatibility complex class II. Maximal atherosclerotic lesion area was determined in a masked fashion. Plasma interleukin (IL)-6 was analyzed with ELISA, and triglycerides were determined with a kit from Sigma Aldrich (St Louis, MO).
Additional Methods
General laboratory methods and a more detailed description of methods are provided in the online-only Data Supplement.
Statistical Analyses
Prism4 (GraphPad Software, Inc, La Jolla, CA) was used for statistical analysis. Unpaired Student t test was used to compare 2 groups. One-or 2-way ANOVA was used to compare Ͼ2 groups or parameters with the Tukey and Bonferroni posthoc tests, respectively. Values of PϽ0.05 were considered statistically significant.
All P values are based on 2-tailed analyses.
Results
Bone Marrow S100A9 Deficiency Does Not Diminish Atherosclerosis in LDLR ؊/؊ Mice
Whole-body S100A9 deficiency reduces atherosclerosis in apolipoprotein E-deficient (ApoE Ϫ/Ϫ ) mice through reduced arterial macrophage accumulation. 2 We therefore asked whether bone marrow-specific deletion of S100A9 would recapitulate the effect of whole-body S100A9 deficiency on atherosclerosis. Bone marrow from S100A9 ϩ/ϩ and S100A9 Ϫ/Ϫ mice was transplanted into irradiated male LDLR Ϫ/Ϫ mice. The mice were fed chow or DDC for 24 weeks to allow the development of atherosclerosis and insulin resistance ( Figure 1A ). Successful chimerism was confirmed by several different methods. Thus, S100A9 mRNA was undetectable in circulating blood cells from mice that had received S100A9-deficient bone marrow, whereas S100A8 mRNA levels were unchanged ( Figure 1B ). Accordingly, blood clots from LDLR Ϫ/Ϫ S100A9 Ϫ/Ϫ bone marrow chimeras exhibited no detectable S100A9 immunoreactivity despite the presence of neutrophils identified by the neutrophil marker Ly6G, whereas clear S100A9-positive cells were identified in the wild-type controls ( Figure 1C ). Bone marrow cells from S100A9-deficient mice differentiated in the presence of granulocyte macrophage or macrophage colonystimulating factor also showed loss of S100A9 mRNA and loss of both S100A9 and S100A8 protein ( Figure 1D and 1E and Figure I in the online-only Data Supplement), consistent with published results. 11, 12 DDC-fed LDLR Ϫ/Ϫ mice exhibited significant increases in plasma cholesterol and triglycerides compared with chow-fed controls, and there was no effect of bone marrow S100A9 deficiency on these parameters (Figure 2A and 2B). Atherosclerosis was analyzed in Movat pentachromestained cross sections from the aortic sinus and the brachiocephalic artery. DDC-fed mice demonstrated larger aortic sinus and brachiocephalic artery lesions than chowfed mice, confirming previous reports ( Figure 2C and Figure IIA in the online-only Data Supplement). 22 However, bone marrow S100A9 deficiency did not modulate lesion area ( Figure 2C and Figure IIA in the online-only Data Supplement). Immunohistochemistry was used to evaluate macrophage, DC, neutrophil, and T-cell accumulation in atherosclerotic tissue. The Mac-2-positive area (identifying both macrophages and DCs; L.B., M.M.A., K.E.B., and J.W.H., unpublished observations) in the aortic sinus and brachiocephalic artery was significantly elevated in the DDC-fed mice compared with chow-fed mice, with no effect of bone marrow S100A9 deficiency ( Figure 2D and Figure IIB in the online-only Data Supplement). In brachiocephalic artery lesions, neutrophils were detected in only 1 of 18 DDC-fed mice ( Figure III in the online-only Data Supplement), suggesting that neutrophils do not play a significant role in this model, at least not at this time point. Likewise, no CD3 ϩ T cells were detected in sinus lesions (data not shown). Importantly, S100A9 Ϫ/Ϫ bone marrow chimeras had undetectable S100A9 immunoreactivity in Mac-2-positive areas in sinus lesions ( Figure 2E and 2F), confirming successful chimerism. Finally, there were no differences in necrotic core size or other lesion morphological features between mice with S100A9 ϩ/ϩ and S100A9 Ϫ/Ϫ bone marrow (data not shown). Thus, S100A9 deficiency in bone marrowderived cells is not sufficient to reduce atherosclerosis or accumulation of macrophages/DCs in LDLR Ϫ/Ϫ mice.
S100A9 Deficiency Does Not Affect Insulin Resistance
Adipose tissue inflammation, with accumulation of immune cells, is believed to play a causal role in insulin resistance, 23 and TLR4 expression on hematopoietic cells promotes this effect. 24 Male DDC-fed LDLR Ϫ/Ϫ mice develop insulin resistance, obesity, systemic inflammation, and macrophage infiltration into epididymal adipose tissue. 22 We therefore investigated whether S100A9 deficiency would affect these parameters.
Chow-fed LDLR Ϫ/Ϫ mice showed stable body weight, whereas DDC-fed mice gained a significant amount of weight during the 24-week study ( Figure 3A ) and exhibited increased epididymal fat pad weight ( Figure 3B ). Bone marrow S100A9 deficiency results in loss of S100A9 in leukocytes. Irradiated male low-density lipoprotein receptor-deficient mice received wild-type (BM_A9 ϩ/ϩ ) or S100A9-deficient (BM_A9 Ϫ/Ϫ ) bone marrow. A, Three weeks later, some mice were switched to diabetogenic diet with cholesterol (DDC) and maintained for 24 weeks. B, Blood was collected 27 weeks after transplantation; erythrocytes were lysed; and leukocyte RNA was extracted. S100A8 and S100A9 mRNA was determined with semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) and normalized to 18S. C, Blood clots were stained for Ly6G (neutrophils) and S100A9 to determine chimerism. Representative S100A9positive and Ly6G-positive cells are indicated by arrows; bars are 250 m. Bone marrow cells were differentiated in 10 ng/mL granulocyte macrophage colony-stimulating factor for 5 days. S100A8 and S100A9 mRNA and protein levels were analyzed by semiquantitative RT-PCR (D) and Western blot (E). The experiments were repeated several times with similar results. GTT indicates glucose tolerance test; ITT, insulin tolerance test.
There was, however, no difference in weight gain or fat pad mass between LDLR Ϫ/Ϫ mice with S100A9 ϩ/ϩ and S100A9 Ϫ/Ϫ bone marrow ( Figure 3A and 3B). Systemic inflammation, as detected by circulating IL-6, was increased in DDC-fed mice, but bone marrow S100A9 deficiency had no significant effect ( Figure 3C ). The epididymal Mac-2-positive area was significantly increased in DDC-fed mice compared with chow-fed mice ( Figure 3D and 3E). However, there was no significant difference in mice with S100A9 ϩ/ϩ and S100A9 Ϫ/Ϫ bone marrow ( Figure 3D ).
To evaluate insulin resistance, we conducted glucose and insulin tolerance tests. DDC-fed mice had significantly elevated baseline glucose and increased insulin resistance compared with chow-fed mice ( Figure 3F and 3G). Similar to the lack of difference in adipose inflammation and body weight, there was no effect of bone marrow S100A9 deficiency on glucose and insulin tolerance tests ( Figure  3F and 3G).
Although S100A8 and S100A9 are expressed primarily in myeloid cells, evidence suggests that inflammatory stimuli induce their expression in nonmyeloid cells, including endothelial cells. 19, 20 Accordingly, in isolated mouse heart endothelial cells, S100A8 mRNA expression was increased after tumor necrosis factor-␣ treatment compared with controls ( Figure IV in the online-only Data Supplement). This suggests that under proinflammatory conditions such as those present in diet-induced obesity, nonhematopoietic cells may express increased levels of S100A8/A9. Secreted S100A8/A9 from unstimulated or tumor necrosis factor-␣-stimulated endothelial cells were below detection (data not shown), indicating that endothelial cells secrete lower amounts of these proteins than do myeloid cells or do not release these proteins unless damaged.
To assess the potential role of S100A8/A9 in nonhematopoietic cells, whole-body S100A9 ϩ/ϩ and S100A9 Ϫ/Ϫ C57BL/6J male mice were fed chow or DDC for 12 weeks. DDC-fed animals gained a significant amount of weight compared with chow-fed mice with no effect of S100A9 deficiency on body weight or fat pad weight ( Figure 4A and 4B). After 11 to 12 weeks on DDC, the mice displayed glucose intolerance, yet whole-body S100A9 deficiency had no significant effect on insulin or glucose tolerance ( Figure 4C and 4D) . Although DDC-fed mice exhibited increased accumulation of Mac-2-positive cells in epidid- . DDC feeding significantly increased plasma cholesterol, plasma triglycerides, sinus lesion area, and Mac-2 area (all PϽ0.001 vs chow), but bone marrow S100A9 deficiency had no effect on any of these parameters (PϾ0.05). Representative BM_A9 ϩ/ϩ (E) and BM_A9 Ϫ/Ϫ (F) aortic sinus sections were stained with a Movat pentachrome method, anti-Mac-2, anti-Ly6G, anti-S100A9, or relevant negative control IgGs. Bar represents 500 m. ymal adipose tissue ( Figure 4E and 4F), S100A9 deficiency had no effect (data not shown). Together, these results demonstrate that neither bone marrow S100A9 deficiency nor whole-body S100A9 deficiency affects adipose tissue inflammation, obesity, or diet-induced insulin resistance.
Neutrophils, Early Differentiation Stages of Macrophages and DCs, and More Mature DCs Express Significantly More S100A9 Than Do Macrophages
To investigate the reason(s) for the unexpected lack of effect of bone marrow S100A9 deficiency on atherosclerosis, we performed a number of studies. First, expression levels of S100A9 in different myeloid cell populations were determined. S100A8 and S100A9 mRNA levels were analyzed in neutrophils, immature macrophages and DCs, and more mature macrophages and DCs in wild-type mice. S100A8 and S100A9 mRNA levels were markedly higher in thioglycollate-elicited neutrophils compared with thioglycollate-elicited macrophages ( Figure 5A and 5B), consistent with previous studies. 9 S100A9 protein levels were also higher in neutrophils compared with macrophages ( Figure 5C ). S100A8 and S100A9 mRNA levels declined rapidly during macrophage and DC differentiation ( Figure 5D and data not shown), as expected. 9 Next, we investigated the levels of S100A8/A9 in bone marrow-derived DCs differentiated in the presence of granulocyte macrophage colony-stimulating factor-compared with macrophage colony-stimulating factor-differentiated macrophages. The DC population expressed higher levels of the DC markers CD11c and major histocompatibility complex class II ( Figure V in the online-only Data Supplement). DCs expressed more S100A8 and S100A9 mRNA and protein ( Figure 6A through 6C) compared with macrophages.
In parallel experiments, the relative levels of secretion of S100A8 and S100A9 were evaluated by mass spectrometry. Both S100A8 and S100A9 were secreted at significantly elevated levels from DCs compared with macrophages ( Figure 6D-E) .
LPS plus IFN␥ was used to address the expression changes of S100A9 in macrophages and DCs subjected to inflammatory stimuli. In macrophages, LPS/IFN␥ had no effect on S100A8 and S100A9 mRNA ( Figure 6A and 6B) Figure 3 . Bone marrow S100A9 deficiency does not affect insulin resistance. Male low-density lipoprotein receptor-deficient mice were transplanted with wild-type (BM_A9 ϩ/ϩ ) or S100A9deficient (BM_A9 Ϫ/Ϫ ) bone marrow and fed chow or diabetogenic diet with cholesterol (DDC) for 24 weeks. A, Body weights were normalized to starting body weight. Two-way ANOVA was used to evaluate the effect of diet (chow vs DDC) over time (weeks) on body weight (percent change from baseline), followed by Bonferroni posthoc analysis to compare the effect of S100A9 deficiency (BM_A9 ϩ/ϩ versus BM_A9 Ϫ/Ϫ ). DDC feeding significantly increased body weight (PϽ0.001) compared with chow feeding in both BM_A9 ϩ/ϩ and BM_A9 Ϫ/Ϫ mice, but there were no differences between BM_A9 ϩ/ϩ mice and BM_A9 Ϫ/Ϫ mice fed chow or DDC (PϾ0.05). Chow-fed BM_A9 ϩ/ϩ mice, nϭ6; chow-fed BM_A9 Ϫ/Ϫ , nϭ6; DDC-fed BM_A9 ϩ/ϩ , nϭ12; DDC-fed BM_A9 Ϫ/Ϫ , nϭ9. B, Epididymal fat pad weight. Twoway ANOVA was used to evaluate the effect of diet (chow vs DDC) and genotype (BM_A9 ϩ/ϩ vs BM_A9 Ϫ/Ϫ mice) on epididymal weight (g), followed by Bonferroni posthoc analysis. DDC feeding significantly increased epididymal weight (PϽ0.001), but bone marrow S100A9 deficiency had no effect (PϾ0.05). C, Plasma interleukin (IL)-6 was measured by ELISA. Statistical analysis was performed with an unpaired 2-tailed Student t test on IL-6 levels (ng/mL) in DDC-fed mice. Bone marrow S100A9 deficiency had no effect (PϾ0.05). D, Mac-2-positive area was quantified in 3 epididymal fat sections/animal. Two-way ANOVA was used to evaluate the effect of diet (chow vs DDC) and genotype (BM_A9 ϩ/ϩ versus BM_A9 Ϫ/Ϫ mice) on Mac-2 area (m 2 ), followed by Bonferroni posthoc analysis. DDC feeding significantly increased Mac-2 area (PϽ0.001), but bone marrow S100A9 deficiency had no effect (PϾ0.05). E, Representative sections of anti-Mac-2-stained epididymal sections. Glucose tolerance test (GTT; F) and insulin tolerance test (ITT; G) were conducted after 20 and 22 weeks on diet, respectively. Twoway ANOVA was used to evaluate the effect of diet (chow vs DDC) as a function of area under the curve on blood glucose (mg/dL), followed by Bonferroni posthoc analysis. DDC feeding significantly increased the area under the curve for both ITT and GTT (both PϽ0.001), but bone marrow S100A9 deficiency had no effect (PϾ0. or secretion of S100A8 and S100A9 ( Figure 6D and 6E) , although there was some increase in cellular S100A8 and S100A9 protein ( Figure 6C and Figure II in the online-only Data Supplement). The levels of S100A8 and S100A9 in macrophages stimulated with LPS/IFN␥ were consistently lower than those of DCs ( Figure 6A through 6E ). DCs stimulated with LPS plus IFN␥, agents known to result in maturation of DCs, demonstrated reduced S100A8 and S100A9 mRNA levels compared with those of nonstimulated DCs ( Figure 6A and 6B ), but cellular S100A8/A9 protein levels ( Figure 6C ) and secretion of S100A9 remained high ( Figure VI in the online-only Data Supplement). Thus, classic activation of macrophages by LPS/ IFN␥ fails to induce S100A8 and S100A9 to levels seen in DCs. Furthermore, DDC feeding did not induce S100A8 or S100A9 mRNA in peritoneal macrophages from LDLR Ϫ/Ϫ hypercholesterolemic insulin-resistant mice ( Figure VII in the online-only Data Supplement); a high-fat diet also did not affect secretion of S100A8 or S100A9 from peritoneal macrophages. 25 In atherosclerotic lesions, S100A9 immunoreactivity was frequently present primarily in areas positive for Mac-2 ( Figure 6F ), a marker of macrophages and DCs (L.B., M.M.A., K.E.B., J.W.H., unpublished observations). The S100A9-positive area also contained occasional cells positive for major histocompatibility complex class II ( Figure 6F ). Few lesions (5% of lesions analyzed) showed . Whole-body S100A8/A9 deficiency does not improve insulin resistance. Whole-body S100A9 ϩ/ϩ (A9 ϩ/ϩ ) and S100A9 Ϫ/Ϫ (A9 Ϫ/Ϫ ) male mice were fed chow or diabetogenic diet with cholesterol (DDC) for 12 weeks. A, Body weights were normalized to starting body weight. Two-way ANOVA was used to evaluate the effect of diet (chow vs DDC) on body weight (percent change from baseline) as a function of time (weeks), followed by Bonferroni posthoc analysis. DDC feeding significantly increased body weight (PϽ0.001) in A9 ϩ/ϩ and A9 Ϫ/Ϫ mice, but S100A9 deficiency had no effect (PϾ0.05). Chow-fed A9 ϩ/ϩ mice, nϭ3; chow-fed A9 Ϫ/Ϫ , nϭ3; DDC-fed A9 ϩ/ϩ , nϭ4; DDC-fed A9 Ϫ/Ϫ , nϭ7. B, Epididymal fat pad weight was measured. Two-way ANOVA was used to evaluate the effect of diet (chow vs DDC) on epididymal weight (g), followed by Bonferroni posthoc analysis. DDC feeding significantly increased epididymal weight (PϽ0.001), but bone marrow S100A9 deficiency had no effect (PϾ0.05). Glucose tolerance test (GTT; C) and insulin tolerance test (ITT; D) were conducted after 10 and 12 weeks on diet, respectively. Two-way ANOVA was used to evaluate the effect of diet (chow vs DDC) as a function of time (minute) on blood glucose (mg/dL), followed by Bonferroni posthoc analysis. DDC feeding significantly increased area under the curve for the GTT (PϽ0.001), but S100A9 deficiency had no effect (PϾ0.05). DDC feeding did not significantly increase area under the curve for ITT (PϾ0.05), nor was there an effect of S100A9 deficiency. Chow-fed A9 ϩ/ϩ mice, nϭ3; chow-fed A9 Ϫ/Ϫ , nϭ3; DDC-fed A9 ϩ/ϩ , nϭ3; DDC-fed A9 Ϫ/Ϫ , nϭ4 (C) or nϭ7 (D). Results are presented as meanϩSEM or meanϮSEM (A, C, and D) or as scatterplots with meanϮSEM indicated by horizontal lines and vertical lines, respectively (B). Representative Mac-2-stained epididymal sections from chow-fed (E) and DDC-fed (F) S100A9 ϩ/ϩ mice. Bar represents 200 m in E and F. Figure 5 . Neutrophils and monocytes express more S100A8 and S100A9 than do macrophages. Thioglycollate-elicited neutrophils (Neut) and macrophages (Mac) were obtained from C57BL/6 mice. S100A8 (A; nϭ6) and S100A9 (B; nϭ6) mRNA levels were measured by real-time polymerase chain reaction. Cellular S100A9 protein and ␤-actin levels were measured in macrophages and neutrophils. Statistical analysis to compare levels in macrophages and neutrophils was performed by unpaired Student t test (*PϽ0.05). A representative Western blot is shown; images are from the same blot (C). Bone marrow from C57BL/6 mice was collected and enriched for monocytes. Monocytes were cultured in 30% L-conditioned medium. S100A8 and S100A9 mRNA was expressed relative to day 8 (D; nϭ3). One-way ANOVA was used to evaluate S100A9 and S100A8 mRNA as a function of time (days), followed by Tukey posthoc test (*PϽ0.05, **PϽ0.01 for S100A9 mRNA vs S100A9 mRNA day 0; ••PϽ0.01 for S100A8 mRNA vs S100A8 mRNA at day 0). Results are presented as meanϩSEM or meanϮSEM (A, B, and D). occasional cells positive for the neutrophil marker Ly6G. Thus, it is unlikely that neutrophils represent a major source of S100A9 in lesions from LDLR Ϫ/Ϫ mice. A similar pattern of S100A9 immunoreactivity was apparent in the crown-like structures of inflamed adipose tissue, whereas adipocytes themselves were negative for S100A9 ( Figure 6G) .
Thus, S100A9 is expressed at higher levels in neutrophils and early differentiation stages of macrophages and DCs than in mature DCs, which in turn show higher expression and secretion of S100A8 and S100A9 than mature resting or activated macrophages. Immunohistochemical analyses indicate that early differentiation stages of macrophages and DCs or mature DCs are likely sources of S100A9 in lesions of atherosclerosis and inflamed adipose tissue.
S100A9-Deficient Neutrophils Have a Blunted Inflammatory Response and Show Reduced Accumulation in Inflamed Adipose Tissue
We next asked whether S100A9 deficiency has similar effects in these different myeloid cell populations. S100A9-deficient neutrophils elicited from the peritoneal cavity and then stimulated with LPS released significantly less tumor necrosis factor-␣ and monocyte chemoattractant protein-1 than wild-type neutrophils ( Figure 7A-B) . Thus, S100A9 and/or S100A8 has a proinflammatory role in neutrophils.
Neutrophils infiltrate adipose tissue in mice within the first 2 weeks of fat feeding. 26 We therefore investigated neutrophil accumulation in epididymal fat in DDC-fed whole-body S100A9 ϩ/ϩ and S100A9 Ϫ/Ϫ mice. Myeloperoxidase mRNA was used as a sensitive neutrophil marker. After 14 days of DDC feeding, myeloperoxidase mRNA was detectable in adipose tissue from wild-type mice but not in adipose tissue from S100A9 Ϫ/Ϫ mice ( Figure 7C ). The number of neutrophils in S100A9 ϩ/ϩ mice was low; Ͻ1 neutrophil per cross section was identified (data not shown). Conversely, no differences in CD68 mRNA, used as a macrophage and DC marker, were observed between S100A9 ϩ/ϩ and S100A9 Ϫ/Ϫ adipose tissue (data not shown). This suggests that S100A9 deficiency inhibits neutrophil infiltration into adipose tissue, corroborating Figure 6 . Dendritic cells (DCs) express and secrete more S100A8 and S100A9 than macrophages. Bone marrow-derived macrophages (M) or DCs (D) were cultured in L-conditioned medium as a source of macrophage colony-stimulating factor (M-CSF; macrophages) or granulocyte macrophage colony-stimulating factor (GM-CSF; DCs). Some cells were stimulated with lipopolysaccharide (LPS) plus interferon-␥ (IFN␥) during the last 24 hours. S100A8 (A; nϭ3) and S100A9 (B; nϭ3) mRNA levels were measured by real-timepolymerase chain reaction. Cells from the same mice were used in A and B. Statistical analysis was performed by repeated measures 1-way ANOVA for S100A8 and S100A9 mRNA (fold over macrophage), followed by Tukey posthoc test. Macrophage vs DC: ***PϽ0.001 in A and **PϽ0.01 in B; DC vs macrophage LPSϩIFN␥: ***PϽ0.001; DC vs DC LPSϩIFN␥: **PϽ0.01; other comparisons: PϾ0.05. C, Cellular S100A8, S100A9, and ␤-actin levels were evaluated by Western blot. D and E, Macrophages were differentiated for 7 days, followed by LPSϩIFN␥ activation for 24 hours. DCs were cultured for 9 days. Conditioned media were collected, and secreted S100A8 (D; nϭ5) and S100A9 (E; nϭ5) were analyzed by tandem mass spectrometry. Statistical analysis was performed by 1-way ANOVA for secreted S100A8 and S100A9 (spectral evidence that S100A9 plays an important role in promoting neutrophil migration and their inflammatory status.
S100A9-Deficient DCs Display an Enhanced Inflammatory Response to TLR2 and TLR4 Ligands
In contrast to neutrophils, S100A9 Ϫ/Ϫ bone marrowderived DCs stimulated with LPS plus IFN␥ exhibited significant increases in IL-12p40 secretion and iNOS mRNA levels ( Figure 8A and 8B ), 2 markers of inflammatory status, compared with S100A9 ϩ/ϩ DCs. The enhanced proinflammatory response of S100A9 Ϫ/Ϫ DCs was confirmed in bone marrow DCs purified by CD11c ϩ selection. In the CD11c ϩ DC population, LPS and Pam3CSK4, TLR4 and TLR2/1 agonists, respectively, induced a significantly higher release of IL-6 from S100A9-deficient DCs compared with wild-type DCs (Figure 8C and 8D) . Zymosan, another TLR2 ligand, elicited a similarly enhanced effect on IL-12p70 release in S100A9 Ϫ/Ϫ DCs ( Figure VIIA Furthermore, S100A9 Ϫ/Ϫ DCs activated with LPS plus IFN␥ significantly increased T-cell proliferation compared with wild-type DCs ( Figure 8E ). Addition of exogenous recombinant S100A8 and S100A9 did not affect T-cell proliferation in the presence of unstimulated DCs (data not shown), yet in both wild-type and S100A9 Ϫ/Ϫ DCs activated by LPS and IFN␥, exogenous S100A8/A9 signifi-cantly reduced T-cell proliferation ( Figure 8F ). Thus, S100A8 and S100A9 have inhibitory functions in activated DCs, an effect due in part to secreted S100A8/A9 acting in an autocrine fashion.
The inflammatory response of S100A9-deficient macrophages was also investigated. Neither bone marrow-derived macrophages nor thioglycollate-elicited S100A9deficient peritoneal macrophages showed a difference in LPS-induced proinflammatory gene expression; in tumor necrosis factor-␣, IL-12p40, or monocyte chemoattractant protein-1 release; or in zymosan-induced IL-12p40 release compared with S100A9 ϩ/ϩ macrophages ( Figure VIIB through VIID in the online-only Data Supplement and data not shown).
Thus, DCs from S100A9-deficient mice exhibit an increased proinflammatory response and an increased ability to induce T-cell proliferation, whereas S100A9 deficiency in macrophages has no effect on their inflammatory response to TLR ligands.
Discussion
We demonstrate that despite the majority of S100A9 being derived from circulating myeloid cells, bone marrowspecific S100A9 deficiency is not sufficient to reduce systemic inflammation, insulin resistance, or atherosclerosis in fat-fed LDLR Ϫ/Ϫ mice. We propose that the lack of a net effect of S100A9 deficiency in bone marrow-derived cells is explained by our findings that 3 different myeloid cell populations-neutrophils, macrophages, and DCsrespond in distinctly different ways after inflammatory activation in the setting of S100A9 deficiency. We further propose that the relative involvement of distinct myeloid cell populations is likely to explain the inconsistent effects of S100A9 deficiency in inflammatory diseases. 2, 18, 27 A limitation of our study is that myeloid cell populations from adipose tissue and the artery wall of insulin-resistant hyperlipidemic mice were not evaluated because of the difficulty of obtaining large enough quantities of wellcharacterized myeloid cell populations from tissues. Such studies would provide further insight into the role of S100A9 in vivo. Another limitation is that small significant differences might have been detected with larger groups of mice. S100A8 and S100A9 play important roles in neutrophil migration 11 and NADPH oxidase activation. 28 S100A9 deficiency inhibits inflammation in models of sepsis and pancreatitis. 6 -8 These disorders are partially mediated by neutrophils, consistent with our present findings, which demonstrate reduced neutrophils in inflamed adipose tissue of fat-fed S100A9-deficient mice. Together, these findings suggest that S100A9 deficiency reduces neutrophil-mediated inflammation. Conversely, S100A9 inhibits DC maturation, 18 and our data suggest that S100A9 deficiency increases the inflammatory response of DCs. We propose that S100A9 deficiency in diseases in which DCs play a more prominent role will result in increased tissue inflammation. S100A8/A9 have been shown to predict cardiovascular events 1, 29 and are highly expressed in rupture-prone le- Figure 7 . S100A9-deficient neutrophils secrete less tumor necrosis factor-␣ (TNF-␣) and monocyte chemoattractant protein-1 (MCP-1). Thioglycollate-elicited peritoneal neutrophils were obtained from S100A9 ϩ/ϩ and S100A9 Ϫ/Ϫ mice and stimulated with 250 ng/mL lipopolysaccharide (LPS) overnight. TNF-␣ (A) and MCP-1 (B) were measured in conditioned media by ELISA. The results are presented as meanϩSEM (A and B). Statistical analysis was performed by 1-way ANOVA for TNF-␣ and MCP-1 secretion (pg/mg protein), followed by Tukey posthoc test. A9 ϩ/ϩ and A9 Ϫ/Ϫ control vs A9 ϩ/ϩ LPS: ***PϽ0.001; A9 ϩ/ϩ LPS vs A9 Ϫ/Ϫ LPS: ***PϽ0.001; other comparisons: PϾ0.05. nϭ3 except for LPS-stimulated cells in A (nϭ4). C, Epididymal adipose tissue harvested from 3 S100A9 ϩ/ϩ and S100A9 Ϫ/Ϫ mice after a 2-week regimen on diabetogenic diet with cholesterol. Levels of myeloperoxidase (MPO) mRNA were evaluated by reverse transcriptase polymerase chain reaction in each mouse. sions 30 and at the site of coronary occlusion, 30, 31 and whole-body S100A9 deficiency inhibits atherosclerosis in ApoE Ϫ/Ϫ mice. 2 Therefore, S100A8/A9 play an important role in atherosclerosis. However, we show that LDLR Ϫ/Ϫ mice transplanted with S100A9-deficient bone marrow do not exhibit reduced atherosclerosis or macrophage accumulation in lesions. A potential reason for this difference is that the previous report 2 used mice with wholebody S100A9 deficiency in contrast to our bone marrow transplantation study. Several reports have identified inducible expression of S100A8 and/or S100A9 in nonmyeloid cells. 19 ,20 S100A8/A9 can induce chemotactic factor expression in endothelial cells, 32 impair endothelial integrity, 33 and promote smooth muscle proliferation. 34 Given that S100A8/A9 have extracellular actions, 6,14 -15,32 nonmyeloid cell-derived S100A8/A9 may also act in a paracrine fashion on artery wall cells. In addition, ApoE itself has significant effects on macrophage function, 25 and ApoE mice show a significant number of neutrophils in the shoulder regions of atherosclerotic lesions. 35 Interestingly, DCs contribute to lesion development in LDLR Ϫ/Ϫ mice. 36 Thus, part of the difference between the present study and that of Croce et al 2 could be due to differences in lesion myeloid cell composition between ApoE Ϫ/Ϫ and LDLR Ϫ/Ϫ mice.
Conclusions S100A8/A9 differentially modulate the inflammatory responses of myeloid cells in diametrically opposed manners. S100A8/A9 are proinflammatory in neutrophils, have no detectable inflammatory effects in macrophages, and are antiinflammatory in DCs. The main source of S100A9 in lesions of atherosclerosis, at least in LDLR Ϫ/Ϫ mice, appears to be early macrophages or DCs. Further study is needed to fully understand the functions of S100A8/A9 in specific cell populations and disease states before S100A8/A9 are considered therapeutic targets. Figure 8 . S100A9-deficient dendritic cells (DCs) display increased proinflammatory properties. Bone marrow-derived DCs from S100A9 ϩ/ϩ or S100A9 Ϫ/Ϫ mice were activated with lipopolysaccharide (LPS) and interferon-␥ (IFN␥). Secreted interleukin (IL)-12p40 was measured by ELISA (A) and inducible nitric oxide synthase (iNOS) mRNA was measured with real-time polymerase chain reaction (B). Statistical analysis was performed by 1-way ANOVA for IL-12 secretion (ng/mg cellular protein) or iNOS mRNA (fold over wild-type control), followed by Tukey posthoc test. A, A9 Ϫ/Ϫ control cells vs A9 Ϫ/Ϫ LPS-stimulated cells and A9 Ϫ/Ϫ LPS-stimulated cells vs A9 ϩ/ϩ control cells or A9 ϩ/ϩ LPS-stimulated cells: ***PϽ0.001. B, A9 Ϫ/Ϫ and A9 ϩ/ϩ control cells vs A9 Ϫ/Ϫ LPSstimulated cells, A9 ϩ/ϩ control cells vs A9 ϩ/ϩ LPSstimulated cells, and A9 ϩ/ϩ LPS-stimulated cells vs A9 Ϫ/Ϫ control cells or A9 Ϫ/Ϫ LPS-stimulated cells: *PϽ0.05. Other comparisons: PϾ0.05. CD11c ϩ -purified DCs were stimulated with LPS (C) or Pam3CSK4 (D). IL-6 secretion was measured by ELISA. Two-way ANOVA was used to evaluate the effect of S100A9 deficiency on IL-6 secretion (ng/ mL) as a function of LPS and Pam3CSK4 concentration (ng/mL). LPS and Pam3CSK4 significantly increased IL-6 secretion (PϽ0.001). S100A9 deficiency significantly increased IL-6 secretion in response to LPS compared with wild-type controls (*PϽ0.05) and Pam3CSK4 (***PϽ0.01). CD4 ϩ / CD8 ϩ T lymphocytes from BALB/c mice were mixed with control DCs and stimulated DCs obtained from S100A9 ϩ/ϩ and S100A9 Ϫ/Ϫ mice in the absence (E) or presence (F) of 10 g/mL exogenous S100A8/A9. T-cell proliferation was estimated by [ 3 H]-thymidine incorporation. Statistical analysis was performed by unpaired Student t test between groups indicated by lines (*PϽ0.05). The results are presented as meanϩSEM; nϭ3.
